| Identification | Back Directory | [Name]
AMD 3465 (*Hexahydrobromide*) | [CAS]
185991-07-5 | [Synonyms]
CS-810
AMD 3465
AMD3465,98%
GENZ-644494
AMD 3465 (hydrobroMide)
AMD3465;AMD-3465;AMD 3465
AMD 3465 (*Hexahydrobromide*)
AMD3465 R10406hexahydrobromide
1-(2-Pyridinyl)-N-[4-(1,4,8,11-tetraazacyclotetradecan-1-ylMethyl)benzyl]MethanaMine
N-[[4-(1,4,8,11-Tetraazacyclotetradec-1-ylmethyl)phenyl]methyl]-2-pyridinemethanamine hexahydrobromide | [Molecular Formula]
C24H38N6 | [MDL Number]
MFCD20926342 | [MOL File]
185991-07-5.mol | [Molecular Weight]
410.599 |
| Chemical Properties | Back Directory | [Melting point ]
>200°C (dec.) | [storage temp. ]
-20°C | [solubility ]
DMSO (Slightly), Methanol (Very Slightly), Water (Slightly) | [form ]
powder | [color ]
white to light brown |
| Hazard Information | Back Directory | [Uses]
AMD 3465 is a CXCR4 antagonist and in combination with monoclonal antibody, was shown to be potentially effective in reducing tumor growth and increasing survival in patient with B cell lymphoma | [Biochem/physiol Actions]
AMD3465 is also termed as{N-[1,4,8,11-tetraazacyclotetradecanyl-1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine}. It controls oncogenic signaling and invasiveness in vitro. It inhibits breast cancer growth and metastasis in vivo. As a chemokine receptor 4 (CXCR4) antagonist, AMD3465 is ten times more efficient than bicyclam AMD3100. | [storage]
Store at -20°C |
|
|